Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's Why
01:02pm, Wednesday, 28'th Apr 2021
Apellis Pharmaceuticals, Inc. (APLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
07:00am, Wednesday, 21'st Apr 2021
WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the comp
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
12:44pm, Friday, 16'th Apr 2021
WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstr
Amazon, Chipotle, Disney and More Friday Afternoon Analyst Calls
12:06pm, Friday, 16'th Apr 2021
With the trading day about halfway over, the broad markets were trading sideways into the weekend, despite the Dow Jones industrials and the S&P 500 setting record intraday highs in the session.
Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?
12:41pm, Saturday, 27'th Mar 2021
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
05:48pm, Wednesday, 17'th Mar 2021
WALTHAM, Mass. and STOCKHOLM, March 17, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the New
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
09:15am, Wednesday, 10'th Mar 2021
WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two l
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Mar 2021
WALTHAM, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compa
Apellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 Patients
05:58am, Friday, 05'th Mar 2021
Following an interim review of mortality data by an independent data monitoring committee (DMC), Apellis Pharmaceuticals Inc (NASDAQ: APLS) will not pursue additional development of APL-9 for the
Apellis Provides Update on APL-9 for Severe COVID-19
04:05pm, Thursday, 04'th Mar 2021
WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the comp
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q4 2020 Results - Earnings Call Transcript
11:13pm, Sunday, 28'th Feb 2021
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q4 2020 Results - Earnings Call Transcript
Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus
11:22am, Friday, 26'th Feb 2021
Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.
Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 Earnings and Revenue Estimates
06:58pm, Thursday, 25'th Feb 2021
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 293.75% and 35.47%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
04:05pm, Thursday, 18'th Feb 2021
WALTHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compa
